Skip to main content
海昇药业 logo

海昇药业 — Investor Relations & Filings

Ticker · 920656 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 271 across all filing types
Latest filing 2025-03-04 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920656

About 海昇药业

https://www.zcpc.net/

Zhejiang Haisheng Pharmaceutical Co., Ltd. specializes in the research, development, production, and sale of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. The company's core product portfolio includes antipyretic and analgesic medications, cardiovascular agents, and various specialty chemical intermediates. It is recognized as a major global supplier of Naproxen and Naproxen Sodium. Haisheng Pharmaceutical maintains rigorous quality control systems compliant with international standards, including Good Manufacturing Practice (GMP) certifications. The company serves a diverse global clientele, providing high-purity chemical components essential for finished dosage form manufacturing. Its technical expertise focuses on chemical synthesis and process optimization to ensure stable supply chains for the pharmaceutical industry.

Recent filings

Filing Released Lang Actions
关于使用闲置自有资金购买理财产品的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Zhejiang Haisheng Pharmaceutical Co., Ltd. regarding the progress of using idle proprietary funds to purchase financial products. It details the authorization, amounts, counterparties, risk controls, and status of these financial investments. The document includes specific dates of board and shareholder meetings approving the use of funds, descriptions of financial products purchased, and risk disclosures. It is a regulatory disclosure about capital management activities, specifically the use of idle funds for cash management and investment in financial products. It does not contain financial statements, earnings data, or management discussion of financial results. It is not a full financial report but an update on financing/capital usage activities. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length is over 5,000 characters and contains substantive details about capital usage, not just a brief announcement or certification, so it is not RPA or RNS. Confidence is high given the detailed financial product investment information and approvals described.
2025-03-04 Chinese
关于使用部分闲置募集资金购买理财产品的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Zhejiang Haisheng Pharmaceutical Co., Ltd. regarding the progress of using part of idle raised funds to purchase financial products. It includes specifics about authorized entrusted financial management, product details, risk control, and investment amounts. The document is a regulatory announcement about the company's financing activities related to the use of idle raised funds for cash management and investment in financial products. It does not contain financial statements, audit opinions, or management discussions of financial results. It is not a report like an annual or interim report, nor is it a call transcript or AGM material. The content fits best under Capital/Financing Update (CAP) as it updates on the company's financing activities and capital usage related to raised funds and investments in financial products.
2025-03-04 Chinese
2024年年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled '2024 年年度业绩快报公告' which translates to '2024 Annual Performance Express Report Announcement'. It contains preliminary financial data for the year 2024, including revenue, profit, and asset figures, but explicitly states that these are preliminary and unaudited figures, with final audited data to be disclosed in the full annual report. The document is relatively short (1576 characters) and serves as an announcement of preliminary annual results rather than a full annual report. It also includes a risk warning about the preliminary nature of the data. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of quarterly or annual financial results with key highlights only, not the full detailed report. Therefore, the correct classification is Earnings Release (ER). FY 2024
2025-02-25 Chinese
浙江天册律师事务所关于浙江海昇药业股份有限公司2025年第一次临时股东大会的法律意见书
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the legality and validity of the procedures and voting results of the 2025 first extraordinary general meeting (临时股东大会) of Zhejiang Haisheng Pharmaceutical Co., Ltd. It details the convening, attendance, voting procedures, and results of the shareholders' meeting. The document does not contain financial statements or financial performance data, nor is it an announcement of a report publication. It is not a management or board change announcement, nor a voting results declaration in the strict sense of official shareholder vote results announcements. Instead, it is a legal opinion on the meeting's procedural compliance and voting validity, which is a type of regulatory/legal proceeding document. Given the nature of the document as a legal opinion letter related to a shareholders meeting, it best fits the category of Legal Proceedings Report (LTR).
2025-02-16 Chinese
公司章程
Governance Information Classification · 100% confidence The document is titled as the "章程" (Articles of Association or Company Bylaws) of Zhejiang Chemsyn Pharm Co., Ltd. It contains detailed provisions about the company's organization, shareholder rights, board structure, shareholder meetings, voting procedures, and other governance matters. It references relevant laws and regulatory bodies such as the China Securities Regulatory Commission and Beijing Stock Exchange rules. The content is a comprehensive governance document outlining internal rules and procedures rather than a financial report, announcement, or meeting minutes. Therefore, it fits the category of Governance Information (CGR). The document length is substantial and contains detailed governance rules, not just an announcement or summary, confirming it is the governance document itself.
2025-02-16 Chinese
2025年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement from the 2025 first extraordinary shareholders' meeting of Zhejiang Haisheng Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, voting results, and legal opinions confirming the validity of the meeting and resolutions. The content focuses on the official announcement of voting results from a shareholders' meeting, including approval of amendments to company bylaws and board rules. There is no financial data, no presentation materials, no management discussion, no audit or earnings information. The document is a formal announcement of voting results from a shareholders' meeting, which fits the category 'Declaration of Voting Results & Voting Rights Announcements (DVA)'. The document length is short (1655 characters), and it is not merely an announcement of a report but the actual voting results. Therefore, the correct classification is DVA with high confidence.
2025-02-16 Chinese

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.